PPL and vitiligo: Except for plectin, no clinical studies currently focus on inhibitors targeting the plakin family.[104,105] Some researchers have developed an agonist, I-3, which targets periplakin and has shown better results in treating vitiligo in in vivo animal tests.[106] A monoclonal antibody manifestation targeting plectin mislocalized on the cell surface of ovarian cancer cells showed promising results in in vivo and in vitro assays.[107] While this holds promise, challenges remain in developing agonists and inhibitors of plakin family members in digestive tumors.